DDD
Drug Delivery and Supply Chain
PacBio and Verily Health announce multi-year strategic collaboration to scale long-read genomics for biomedical AI
PacBio, a developer of advanced sequencing technologies, and Verily Health, a healthcare data intelligence company, have announced a multi-year strategic collaboration to integrate PacBio HiFi...
Clinical Trials Insights
Rapport Therapeutics announces positive topline results from its phase 2 trial of RAP-219 for the treatment of bipolar mania
Rapport Therapeutics, a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders,...
Drug Delivery and Supply Chain
ScionxBio announces collaboration to develop long-acting xRNA therapeutics
ScionxBio has entered into a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialise extended exposure versions of certain Sanofi mRNA...
Clinical Trials Insights
Dr Elizabeth Rohrs of the Royal Columbian Hospital reports a 39% reduction in ICU pneumonia rates among patients treated with nasal photodisinfection at ESICM
Dr Elizabeth Rohrs PhD, RRT, principal investigator at Royal Columbian Hospital (RCH) and RCH Foundation Research Director, recently presented findings from the SMURF (Suppression...
Drug Delivery and Supply Chain
Armenia grants first marketing authorisations for Agenus’ BOT+BAL in previously treated MSS metastatic colorectal cancer
The Ministry of Health of the Republic of Armenia has granted marketing authorisations for Agenus’ Botvymo (botensilimab, BOT) and Evamplix (balstilimab, BAL), each approved for use...
Drug Delivery and Supply Chain
Sterling expands ADC manufacturing capacity and capabilities
Contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions has announced completion of an additional, large-scale GMP manufacturing suite at its dedicated bioconjugation facility...
Finance, mergers and appointments
Bolt Biotherapeutics announces acquisition of Prana Therapies and US$120 million concurrent private placement to advance PRA-216 in multiple high-value inflammatory indications
Bolt Biotherapeutics has acquired Prana Therapies, a clinical-stage biotechnology company pioneering next-generation half-life-extended multi-specific antibodies designed to deliver best-in-disease therapies
Following the acquisition, the company...
Clinical Trials Insights
Muna Therapeutics announces positive phase 1 results supporting potential of oral small-molecule TREM2 modulator, MNA-001, in Alzheimer’s disease
Muna Therapeutics (Muna), a clinical-stage biotechnology company developing innovative treatments for neurodegenerative diseases, has announced positive results from its phase 1 study of MNA-001,...
- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -
Latest stories
© 2026 Pharma Press Global.